<PAGE>
EXHIBIT 99.1
Press Release of the Registrant
CuraGen Corporation Files Shelf Registration
NEW HAVEN, CT - OCTOBER 9, 2000 - CuraGen Corporation (Nasdaq: CRGN), an
integrated genomics-based drug discovery and development company, announced
today that it has filed a Form S-3 shelf registration statement with the
Securities and Exchange Commission for the sale of up to $500 million of various
types of securities.
A registration statement on Form S-3 relating to these securities has been filed
with the Securities and Exchange Commission but has not yet become effective.
These securities may not be sold nor may offers to buy be accepted prior to the
time that the registration statement becomes effective. This news release does
not constitute an offer to sell or the solicitation of an offer to buy the
securities, nor shall there be any sale of the securities in any state in which
such offer, solicitation or sale would be unlawful prior to registration or
qualification of the securities under the securities laws of that state.
CuraGen Corporation is advancing the discovery and development of pharmaceutical
and life science products through the systematic application of genomics.
CuraGen's fully integrated, Internet-based functional genomic technologies,
services, and information systems are designed to rapidly generate comprehensive
information about genes, human genetic variations, gene expression, protein
expression, protein pathways, and potential drugs that affect these pathways.
The Company is applying this comprehensive functional genomic platform to
develop protein and antibody drugs, and to identify small molecule drug targets.
CuraGen has conducted research for collaborators including Abgenix, Biogen, COR
Therapeutics, Dupont/Pioneer Hi-Bred International, Gemini Genomics, Genentech,
Glaxo Wellcome, Hoffmann-La Roche, Ono Pharmaceuticals, and Roche Vitamins.
CuraGen employs over 300 people and is headquartered in New Haven, CT.
Additional Company information is available at www.curagen.com.
- ### -
